natgillin/translations-raw huggingface dataset:
In this study, 24 adult patients received clonazepam (0.025-0.03 mg/kg/day as IV continuous infusions) as anticonvulsant therapy and the PK data of these patients were compared to historical data collected in patients treated with phenytoin. 
V tej študiji je 24 odraslih bolnikov prejelo klonazepam (0,025-0,03 mg/kg/dan z neprekinjeno intravensko infunzijo) kot antikonvulzivno terapijo; farmakokinetične podatke teh bolnikov so primerjali s predhodno zbranimi podatki bolnikov, ki so prejemali fenitoin.
Pharmacotherapeutic group: Antineoplastic agents, alkylating agents, alkyl sulfonates, ATC code: L01AB01. 
Farmakoterapevtska skupina: antineoplastična zdravila, alkilirajoča zdravila, alkilsulfonati, oznaka ATC: L01AB01
The cumulative incidence of neutrophil recovery at day 28 was 98.8% (95%CI, 85.7-99.9%). 
Kumulativna incidenca okrevanja nevtrofilcev na 28. dan je bila 98,8 % (95 % IZ: od 85,7 do 99,9 %).
Dose and administration The dose of busulfan will be calculated according to your body weight. 
Odmerek in uporaba: Odmerek busulfana vam bodo preračunali glede na vašo telesno maso.
Pack size 1 pack containing 8 vials (8 cartons of 1 vial). 
Pakiranje 1 pakiranje, ki vsebuje 8 vial (8 škatel z eno vialo).
The FB combination allowed sufficient myeloablation modulated by the intensity of conditioning regimen through the variation of number of days of busulfan infusion. 
Kombinacija s FB je omogočila zadostno mieloablacijo, modulirano z intenzivnostjo pripravljalne sheme s spreminjanjem števila dni infundiranja busulfana.
As documented in clinical studies, no treated patients experienced cardiac tamponade or other specific cardiac toxicities related to busulfan. 
Kot je dokumentirano v kliničnih raziskavah, se pri nobenem zdravljenem bolniku ni pojavila srčna tamponada ali katera koli druga značilna srčna toksičnost, povezana z busulfanom.
Precautions to be taken before handling or administering the medicinal product This medicinal product must be diluted prior to administration. 
Previdnostni ukrepi, potrebni pred ravnanjem z zdravilom ali dajanjem zdravila To zdravilo je potrebno pred uporabo razredčiti.
Busulfan in combination with fludarabine (FB) 
Busulfan v kombinaciji s fludarabinom (FB)
The consequence of treatment with busulfan at the recommended dose and schedule is profound myelosuppression, occurring in all patients. 
Posledica zdravljenja z busulfanom v priporočenem odmerku in razporedu je globoka mielosupresija, ki se pojavlja pri vseh bolnikih.
Adverse reactions information is derived from two clinical trials (n=103) of busulfan. 
Informacije o neželenih učinkih so pridobljene iz dveh kliničnih preskušanj (n = 103) busulfana.
For the 40% of children < 9 kg outside the target, the AUC was evenly distributed either below or above the targeted limits; i.e. 20% each < 900 and > 1500 µmol/L.min following 1 mg/kg. 
Pri 40 % otrok z maso < 9 kg, izven ciljnega območja, je bil AUC enakomerno porazdeljen pod ali nad ciljnimi omejitvami, to je 20 % < 900 in 20 % > 1500 µmol/l·min po odmerku 1 mg/kg.
Small volumes may be administered over 2 hours using electric syringes. 
Majhne količine lahko damo v dveh urah s črpalko na brizgo.
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2). 
POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE Predpisovanje in izdaja zdravila je le s posebnim režimom (glejte Prilogo I: Povzetek glavnih značilnosti zdravila, poglavje 4.2).
Women of childbearing potential have to use effective contraception during and up to 6 months after treatment. 
Ženskam v rodni dobi priporočamo, da med zdravljenjem in še do 6 mesecev po zdravljenju uporabljajo učinkovito kontracepcijo.
The principal toxic effect is profound myeloablation and pancytopenia but the central nervous system, liver, lungs, and gastrointestinal tract may also be affected. 
Glavna toksična učinka sta huda mieloablacija in pancitopenija, vendar so lahko prizadeti tudi centralni živčni sistem, jetra, pljuča in prebavni trakt.
Busulfan Fresenius Kabi is used in adults, new-born infants, children and adolescents as a treatment prior to transplantation. 
Zdravilo Busulfan Fresenius Kabi se uporablja pri odraslih, novorojenčkih, pri otrocih in mladostnikih kot terapija pred presaditvijo.
The most frequent infectious adverse reactions were Cytomegalovirus (CMV) reactivation [range: 30.7% - 80.0%], Epstein-Barr Virus (EBV) reactivation [range: 2.3% - 61%], bacterial infections [range: 32.0% - 38.9%] and viral infections [range: 1.3% - 17.2%]. 
Najpogostejši infekcijski neželeni učinki so bili reaktivacija citomegalovirusa (CMV) [razpon: 30,780,0 %], reaktivacija virusa Epstein-Barr (EBV) [razpon: 2,3-61 %], bakterijske okužbe [razpon: 32,038,9 %] in virusne okužbe [razpon: 1,3-17,2 %].
Malformations and anomalies included significant alterations in the musculoskeletal system, body weight gain, and size. 
Med malformacije in anomalije so sodile pomembne spremembe mišično-skeletnega sistema, pridobivanje na telesni masi in velikosti.
It is recommended when treating these patients that serum transaminase, alkaline phosphatase, and bilirubin should be monitored regularly 28 days following transplant for early detection of hepatotoxicity. 
Priporočamo, da se med zdravljenjem teh bolnikov 28 dni po transplantaciji redno kontrolira serumske transaminaze, alkalno fosfatazo in bilirubin, za zgodnje odkrivanje hepatotoksičnosti.
The residual medicinal product must not be flushed in the administration tubing as rapid infusion of busulfan has not been tested and is not recommended. 
Preostalega zdravila ne smete izpirati v ceveh med uporabo, saj hitre infuzije busulfana še niso preizkusili in ni priporočena.
It must be considered that overdose of busulfan will also increase exposure to DMA. 
Preveliko odmerjanje busulfana povzroči tudi povečano izpostavljenost DMA.
Adjusted ideal body weight (AIBW) is calculated as follows: AIBW= IBW + 0.25x (actual body weight-IBW). 
Izračun prilagojene idealne telesne mase (AIBW): AIBW = IBW + 0,25 x (dejanska telesna masa - IBW)
In the absence of haematopoietic progenitor cell transplantation, the recommended dose of busulfan would constitute an overdose of busulfan. 
V odsotnosti transplantacije hematopoetskih progenitorskih celic bi priporočeni odmerek busulfana povzročil prevelik odmerek busulfana.
All transfer procedures require strict adherence to aseptic techniques, preferably employing a vertical laminar flow safety hood. 
Vsi postopki prenašanja zdravila zahtevajo strogo upoštevanje aseptičnih postopkov, po možnosti uporabo komore z vertikalnim laminarnim pretokom zraka.
Diseases included were acute leukaemia past first remission, in first or subsequent relapse, in first remission (high risk), or induction failures; chronic melogenous leukaemia in chronic or advanced phase; primary refractory or resistant relapsed Hodgkin's disease or non-Hodgkin's lymphoma, and myelodysplastic syndrome. 
Vključene bolezni so bile: akutna levkemija po prvi remisiji, v prvi ali naslednji ponovitvi, v prvi remisiji (veliko tveganje) ali napake v indukciji, kronična mieloidna levkemija v kronični ali napredovali fazi, primarna refraktarna ali rezistentna ponovljena Hodgkinsova bolezen ali neHodgkinsov limfom ter mielodisplastični sindrom.
Busulfan induced chromosomal aberrations in vitro (rodent and human cell) and in vivo (rodents and humans). 
Busulfan je povzročil kromosomske aberacije in vitro (pri celicah glodavcev in pri človeških celicah) ter in vivo (pri glodavcih in človeku).
Your doctor will monitor your blood counts and liver enzymes regularly to detect and manage these events. 
Zdravnik bo redno spremljal število krvnih celic in jetrne encime, da bi odkril te učinke in primerno ukrepal.
Particular caution should be taken if you use itraconazol and metronidazole (used for certain types of infections) or ketobemidone (used to treat pain), because this may increase the side-effects. 
Bodite posebej previdni, če jemljete itrakonazol in metronidazol (za zdravljenje določenih vrst okužb) ali ketobemidon (za lajšanje bolečin).
In rats, a DMA daily dose of 450 mg/kg given to rats for nine days caused inactive spermatogenesis. 
Pri podganah je 9-dnevno odmerjanje DMA v odmerku 450 mg/kg/dan povzročilo neaktivno spermatogenezo.
Chronic GVHD (c-GVHD) was reported if serious or the cause of death, and was reported as the cause of death in 3 patients. 
O kronični GVHD (cGVHD) so poročali, če je bila resna ali vzrok smrti; poročali so, da je bila vzrok smrti pri 3 bolnikih.
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than the above-mentioned conditions when dilution has taken place in controlled and validated aseptic conditions. 
Če raztopine ne uporabite takoj, so čas shranjevanja med uporabo in pogoji pred uporabo odgovornost uporabnika in običajno ne smejo presegati zgoraj omenjenih pogojev, če je redčenje opravljeno v kontroliranih in validiranih aseptičnih pogojih.
Undesirable effects coming from post-marketing survey have been implemented in the tables with the incidence “not known”. 
Neželeni učinki iz raziskav v obdobju trženja zdravila so v preglednicah prikazani z incidenco "neznana pogostnost".
These include infection and Graft-versus host disease (GVHD) which although not directly related, were the major causes of morbidity and mortality, especially in allogeneic HPCT. 
Te vključujejo infekcijo in reakcijo presadka proti gostitelju (graft-versus-host disease (GVHD)), ki sta glavna vzroka za obolelost in smrtnost, zlasti v primeru alogenske HPCT, čeprav nista neposredno povezana.
10 ml of concentrate for solution for infusion in clear colourless glass vials (type I) with teflon faced rubber stopper and sealed with aluminium flip-off seal. 
10 ml koncentrata za raztopino za infundiranje v prozornih, brezbarvnih steklenih vialah (steklo tipa I) s teflonsko prevlečenim gumijastim zamaškom in zapečatenih z aluminijsko snemno (flip-off) zaporko.
Busulfan dose (mg/kg) 
Odmerek busulfana (mg/kg)
If not used immediately, in-use storage times and conditions are the responsibility of the user and would normally not be longer than the above-mentioned conditions when dilution has taken place in controlled and validated aseptic conditions. 
Če raztopine ne uporabite takoj, so čas in pogoji shranjevanja med uporabo odgovornost uporabnika in običajno ne smejo presegati zgoraj omenjenih pogojev, če je redčenje opravljeno v kontroliranih in validiranih aseptičnih pogojih.
Studies in animals have shown reproductive toxicity (embryo-foetal lethality and malformations) (see section 5.3) 
Študije na živalih so pokazale toksičen vpliv na sposobnost razmnoževanja (embriofetalna smrtnost in malformacije) (glejte poglavje 5.3).
Studies in renally impaired patients have not been conducted, however, as busulfan is moderately excreted in the urine, dose modification is not recommended in these patients. 
Pri bolnikih z okvaro ledvic raziskave niso bile izvedene, ker pa se busulfan zmerno izloča z urinom, pri teh bolnikih odmerka ni priporočljivo spreminjati.
Adverse reactions reported as more than an isolated case are listed below, by system organ class and by frequency. 
Neželeni učinki, o katerih so poročali pri več kot enem primeru, so po organskih sistemih in po pogostnosti razvrščeni spodaj.
No patients were discontinued from treatment due to adverse reactions related to busulfan. 
Nihče od bolnikov ni prekinil terapije zaradi neželenih učinkov, povezanih z busulfanom.
8 MARKETING AUTHORISATION NUMBER(S) EU/1/14/951/001 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/14/951/001
The pharmacokinetics of intravenous busulfan was studied in 124 evaluable patients following a 2-hour intravenous infusion for a total of 16 doses over four days. 
Farmakokinetiko intravensko uporabljenega busulfana so preučevali pri 124 bolnikih, ki jih je bilo možno oceniti, po 2-urni intravenski infuziji, do skupno 16 odmerkov v obdobju 4 dni.
However, more than 500 patients aged ≥ 55 years were reported in publications with FB conditioning regimens, yielding efficacy outcomes similar to younger patients. 
Vendar objave o pripravljalnih shemah FB poročajo o več kot 500 bolnikih, starih ≥ 55 let; dosežena učinkovitost je bila podobna kot pri mlajših bolnikih.
Increase of lactate dehydrogenase in the blood. 
Povišanje laktat-dehidrogenaze v krvi.
Busulfan should not be given by rapid intravenous, bolus or peripheral injection. 
Busulfana ne smete uporabiti v obliki hitre intravenske injekcije, bolusa ali periferne injekcije.
Nutrition: loss of appetite, decrease in magnesium, calcium, potassium, phosphate, albumine in blood, and increase in blood sugar. 
Prehrana: izguba teka, zmanjšanje količine magnezija, kalcija, kalija, fosfata in albumina v krvi ter povišanje sladkorja v krvi.
The incidence of each adverse reactions presented in the following table has been defined according to the highest incidence observed in published clinical trials in RIC regimen for which the population treated with FB was clearly identified, whatever the schedules of busulfan administrations and endpoints. 
Incidenca vsakega neželenega učinka, prikazanega v naslednji preglednici, je opredeljena glede na najvišjo incidenco, opaženo v objavljenih kliničnih preskušanjih s shemo RIC, kjer je bila s FB zdravljena populacija jasno identificirana, ne glede na uporabljeno shemo odmerjanja busulfana ali na opazovane dogodke.
Compared to the four times a day regimen, the once-daily regimen is characterized by a higher peak concentration, no drug accumulation and a wash out period (without circulating busulfan concentration) between consecutive administrations. 
V primerjavi s shemo odmerjanja štirikrat na dan, dosega shema odmerjanja enkrat dnevno višjo najvišjo koncentracijo, je ne spremlja kopičenje zdravila in ima obdobje izpiranja (brez koncentracije busulfana v obtoku) med zaporednimi uporabami.
Data from a recently completed prospective multicentre phase 2 study including 80 patients, aged 18 to 65 years old, diagnosed with different hematologic malignancies who underwent allo-HCT with an FB (3 days of busulfan) reduced intensity conditioning regimen became available. 
Na voljo so podatki nedavno dokončane prospektivne multicentrične študije 2. faze, ki je vključevala 80 bolnikov v starosti od 18 do 65 let, z diagnosticiranimi različnimi hematološkimi malignomi, in opravljeno homologno transplantacijo hematopoetskih celic s pripravljalno shemo FB zmanjšane intenzivnosti (3 dnevi busulfana).
Blood: decrease of blood circulating cells (red and white) and platelets. 
Kri: zmanjšanje števila krvnih celic (rdečih in belih) ter trombocitov v krvnem obtoku.
Since busulfan is mainly metabolized through the liver, caution should be observed when busulfan is used in patients with pre-existing impairment of liver function, especially in those with severe hepatic impairment. 
Ker se busulfan v glavnem presnavlja v jetrih, je priporočljiva posebna previdnost pri uporabi busulfana pri bolnikih z že okvarjeno jetrno funkcijo, zlasti pri tistih s hudo okvaro jeter.
No specific clinical trial was carried out to assess drug-drug interaction between intravenous busulfan and itraconazole or metronidazole. 
Specifičnih kliničnih preskušanj za oceno medsebojne interakcije med intravensko uporabljenim busulfanom in itrakonazolom ali metronidazolom niso izvedli.
The most serious side effects of busulfan therapy or the transplant procedure may include decrease in circulating blood cell counts (intended effect of the medicine to prepare you for your transplant infusion), infection, liver disorders including blocking of a liver vein, graft versus host disease (the graft attacks your body) and pulmonary complications. 
Najresnejši neželeni učinki zdravljenja z busulfanom ali postopka presaditve so zmanjšanje števila krvnih celic v krvnem obtoku (želeni učinek zdravila, ki vas pripravi na transplantacijsko infuzijo), okužba, motnje v delovanju jeter (vključno z blokirano jetrno veno), reakcija presadka proti gostitelju (presadek napade vaše telo) in pljučni zapleti.
Y: body weight of the patient in kg D: dose of busulfan (see section 4.2) 
Y: telesna masa bolnika v kilogramih D: odmerek busulfana (glejte poglavje 4.2)
On the basis of human data, busulfan has been classified by the International Agency for Research on Cancer (IARC) as a human carcinogen. 
Na podlagi podatkov o ljudeh, je Mednarodna agencija za raziskave rakavih obolenj (International Agency for Research on Cancer (IARC)) uvrstila busulfan med človeške kancerogene.
Fast and complete engraftment rates in 80-100% of patients were reported in the majority of studies. 
V večini študij so poročali o hitri in popolni vsaditvi pri od 80 do 100 % bolnikov.
In these studies, a total of 1574 patients received FB as a reduced intensity conditioning (RIC) regimen prior to haematopoietic progenitor cell transplantation. 
V teh študijah je skupno 1.574 bolnikov dobivalo FB v pripravljalni shemi RIC pred transplantacijo hematopoetskih progenitorskih celic.
Busulfan is for intravenous use. 
Busulfan je namenjen intravenski uporabi.
Doses of 400 mg/kg/day DMA administered during organogenesis caused significant developmental anomalies. 
Med organogenezo so odmerki DMA 400 mg/kg/dan povzročili pomembne anomalije v razvoju.
Chemical and physical in-use stability after dilution in glucose 5% or sodium chloride 9 mg/ml (0.9%) solution for injection has been demonstrated for 8 hours (including infusion time) after dilution when stored at 25°C ± 2°C or 12 hours after dilution when stored at 2°C-8°C followed by 3 hours stored at 25°C ± 2°C (including infusion time). 
Kemijska in fizikalna stabilnost med uporabo, po redčenju s 5 % raztopino glukoze ali 0,9 % raztopino natrijevega klorida (9 mg/ml) za injiciranje, sta dokazani do 8 ur (vključno s časom infuzije) po redčenju, če je bila raztopina shranjena pri temperaturi 25 °C ± 2 °C, ali do 12 ur po redčenju, če je bila raztopina shranjena pri temperaturi med 2 in 8 °C in nato 3 ure pri temperaturi 25 °C ± 2 °C (vključno s časom infuzije).
Documentation on the safety and efficacy of busulfan in combination with fludarabine (FB) prior to allogeneic HPCT derives from the literature review of 7 published studies involving 731 patients with myeloid and lymphoid malignancies reporting the use of intravenous busulfan infused once daily instead of four doses per day. 
Dokumentacija o varnosti in učinkovitosti busulfana v kombinaciji s fludarabinom (FB) pred homologno transplantacijo hematopoetskih progenitorskih celic izvira iz pregleda literature 7 objavljenih študij, ki so zajele 731 bolnikov z mieloičnimi in limfatičnimi malignomi in so uporabljale intravensko infundirani busulfan enkrat dnevno, namesto štirih odmerkov na dan.
It seems that the recommended intravenous busulfan dose administered either as an individual infusion (3.2 mg/kg) or into 4 divided infusions (0.8 mg/kg) provided equivalent daily plasma exposure with similar both inter-and intrapatient variability. 
Zdi se, da je priporočeni odmerek intravenskega busulfana v posamezni infuziji (3,2 mg/kg) ali v 4 deljenih infuzijah (0,8 mg/kg) zagotovil enakovredno dnevno izpostavljenost v plazmi, s podobno inter- in intraindividualno variabilnostjo.
- 12 hours after dilution when stored at 2°C-8°C followed by 3 hours stored at 25°C ± 2°C (including infusion time). 
- do 12 ur po redčenju, če je bila raztopina shranjena pri temperaturi med 2 in 8 °C in nato 3 ure pri temperaturi 25 °C ± 2 °C (vključno s časom infuzije).
The literature on busulfan suggests a therapeutic AUC window between 900 and 1500 µmol/L.minute per administration (equivalent to a daily exposure between 3600 and 6000 µmol/L.minute). 
Literatura o busulfanu priporoča terapevtsko AUC območje med 900 in 1.500 µmol/l·min, na uporabo (kar ustreza dnevni izpostavljenosti med 3.600 in 6.000 µmol/l.
- The other ingredients are dimethylacetamide and macrogol 400. 
- Pomožni snovi sta dimetilacetamid in makrogol 400.
Only a clear solution without particles should be used. 
Uporabiti smete le bistro raztopino, brez delcev.
In this regard, for children < 9 kg, a monitoring of the plasma concentrations of busulfan (therapeutic drug monitoring) for dose-adjustment may improve the busulfan targeting performance, especially in extremely young children and neonates. 
Zaradi tega je priporočljivo pri otrocih s telesno maso < 9 kg spremljati plazemske koncentracije busulfana (terapevtsko spremljanje zdravila), ker lahko z uravnavanjem odmerka izboljšamo ciljno učinkovitost busulfana, kar še posebej velja za izjemno majhne otroke in novorojenčke.
PK/PD relationship was observed between stomatitis and AUCs in autologous patients and between bilirubin increase and AUCs in a combined autologous and allogeneic patient analysis. 
FK/FD razmerje so opazili med stomatitisom in vrednostmi AUC pri avtolognih bolnikih, ter med povišanjem vrednosti bilirubina in vrednostmi AUC pri analizi združenih podatkov avtolognih in alogenskih bolnikov.
Gastro-intestinal: bleeding in the stomach and/or the gut. 
Prebavila: krvavitve v želodcu in/ali črevesju.
A total of 14 patients (50%) experienced a-GVHD. 
Skupno 14 bolnikov (50 %) je izkusilo aGVHD.
PHARMACEUTICAL FORM AND CONTENTS Concentrate for solution for infusion 1 vial of 10 ml. 
FARMACEVTSKA OBLIKA IN VSEBINA koncentrat za raztopino za infundiranje 1 viala z 10 ml.
Gastrointestinal disorders The highest frequency of nausea and vomiting was 59.1% and the highest frequency of stomatitis was 
Bolezni prebavil: Največja pogostnost navzee in bruhanja je bila 59,1 % in največja pogostnost stomatitisa 11 %.
Respiratory: decrease in blood oxygen. 
Dihala: zmanjšana koncentracija kisika v krvi.
The incidence of a-GVHD grades I-II was 13% (8/61), while the incidence of grade III-IV was 5% (3/61). 
Pojavnost aGVHD stopnje I-II je bila 13 % (8/61), medtem ko je bila pojavnost stopnje III-IV 5 % (3/61).
The entire prescribed busulfan dose should be delivered over two or three hours depending on the conditioning regimen. 
Infuzija celotnega predpisanega odmerka busulfana mora trajati dve ali tri ure, odvisno od pripravljalne sheme.
The incidence of a-GVHD grades I-II was 46.4% (13/28), while the incidence of grade III-IV was 3.6% (1/28). 
Pojavnost aGVHD stopnje I-II je bila 46,4 % (13/28), medtem ko je bila pojavnost stopnje IIIIV 3,6 % (1/28).
Busulfan must not be infused concomitantly with another intravenous solution. 
Busulfan se ne sme uporabljati sočasno z drugimi intravenskimi raztopinami.
It is recommended to administer anticonvulsants 12 h prior to busulfan to 24 h after the last dose of busulfan. 
Antikonvulzive je priporočeno dajati od 12 ur pred odmerkom busulfana do 24 ur po zadnjem odmerku.
There have been two reports that busulfan is dialyzable, thus dialysis should be considered in the case of an overdose. 
V dveh poročilih je omenjeno, da se busulfan dializira, zato je v primeru prevelikega odmerjanja primerno pretehtati tudi možnost dialize.
Nervous system: confusion, nervous system disorders. 
Živčni sistem: zmedenost, bolezni živčevja.
D: dose of busulfan (see SPC section 4.2) 
D: odmerek busulfana (glejte poglavje 4.2)
Busulfan in combination with cyclophosphamide or melphalan Adverse reactions reported both in adults and paediatric patients as more than an isolated case are listed below, by system organ class and by frequency. 
Busulfan v kombinaciji s ciklofosfamidom ali melfalanom Neželeni učinki pri odraslih in pediatričnih bolnikih, o katerih so poročali pri več kot enem primeru, so po organskih sistemih in po pogostnosti razvrščeni spodaj.
(A ml Busulfan Fresenius Kabi) x (10) = B ml of diluent 
(A ml zdravila Busulfan Fresenius Kabi) x (10) = B ml redčila
Menopausal symptoms and female infertility. 
Simptomi menopavze in neplodnost pri ženskah.
Brain abscess, Inflammation of the skin, generalised infection. 
Možganski absces, vnetje kože, splošna okužba.
QUALITATIVE AND QUANTITATIVE COMPOSITION One ml of concentrate contains 6 mg of busulfan (60 mg in 10 ml). 
KAKOVOSTNA IN KOLIČINSKA SESTAVA En ml koncentrata vsebuje 6 mg busulfana (60 mg v 10 ml).